Test kit for detecting content of 5-hydroxymethyl cytosine and application thereof

Abstract

The invention provides a test kit for detecting the content of 5-hydroxymethyl cytosine and application thereof. The content of a gene marker 5-hydroxymethyl cytosine is detected through the test kit,and the canceration condition of a patient with liver cirrhosis is judged by using the detection result of the content of 5-hydroxymethyl cytosine in the gene marker. The test kit provided by the invention has high accuracy and can quickly react when being applied to liver cancer detection, and has high sensitivity and specificity for liver cirrhosis detection and dynamic monitoring of liver cirrhosis to liver cancer; the operability is high, and detection can be carried out only by collecting venous peripheral blood; compared with a conventional tissue biopsy technology, the detection methodusing the test kit is non-invasive, and can be frequently carried out for many times; the test kit disclosed by the invention is relatively low in detection cost and relatively high in acceptabilityof subjects.

Description

technical field [0001] The invention relates to the technical field of kit detection, in particular to a kit for detecting the content of 5-hydroxymethylcytosine and its application. Background technique [0002] Liver cirrhosis is a common chronic progressive disease clinically, and its pathogenesis is mainly due to liver cirrhosis after hepatitis virus infection. Usually accompanied by upper gastrointestinal bleeding, hepatic encephalopathy, secondary infection, hypersplenism, ascites, cancer and other complications, the probability of liver cirrhosis turning into liver cancer is as high as 70%. Therefore, liver cirrhosis is not only regarded as the etiology of tumors risk factors, but also in the early / middle stage of tumor development. According to the statistics of the World Health Organization, the number of deaths due to liver cirrhosis is second only to malignant tumors, cardiovascular and cerebrovascular diseases and accidents, ranking the fifth cause of death. At...

AI Technical Summary

Problems solved by technology

At present, for high-risk groups of liver cancer such as patients with liver cirrhosis, serum tumor markers are mainly detected clinically, such as the content of alpha-fetoprotein (AFP) in the blood, abnormal prothrombin (DCP), etc., but the sensitivity of the two methods is not enough. 60% and 44%

At the same time, AFP levels are easily affected by pregnancy or other disease factors. For example, in some patients with chronic hepatitis, serum AFP will also increase, which will lead to false positive test results.

In addition, imaging methods such as ultrasonography and CT examination are currently used clinically for diagnosis, but the simple B-ultrasound or CT examination has a high rate of missed diagnosis, and imaging operations are easily affected by operator experience and are dependent on equipment. High and expensive, not suitable for frequent use

This makes most patients unable to get the opportunity of early detection and early treatment, and lose the best treatment period

Images